Rigel (RIGL) Price & Analysis
RIGL Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 789.62M
- Enterprise Value
- CHF 710.20M
- Total Cash (Recent Filing)
- CHF 95.33M
- Total Debt (Recent Filing)
- CHF 39.95M
- Price to Earnings (P/E)
- 2.9
- Beta
- N/A
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 0.76
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Product Growth
Growth across the marketed portfolio supports a more durable commercial foundation than reliance on a single product. TAVALISSE remains the largest contributor, while faster REZLIDHIA growth adds diversification and can improve revenue resilience over the next several quarters.
Profitability And Cash Generation
Strong gross and operating margins, together with positive operating and free cash flow, indicate that Rigel has moved beyond its earlier loss-making profile. This improves its ability to fund development, support commercialization, and withstand execution demands without depending entirely on external capital.
Pipeline And Portfolio Expansion
Adding VEPPANU broadens Rigel from hematology into a potentially sizable oncology market, while R289 provides another differentiated development opportunity. The combination increases portfolio breadth and creates additional long-term growth avenues beyond current marketed therapies.
Bears Say
Recent Revenue Contraction
The latest annualized revenue decline shows that growth has not yet been consistently sustained across the portfolio. Even with positive quarterly product trends, weaker trailing performance increases the need for continued execution in existing brands and successful contribution from newer products.
Liquidity And Expense Pressure
A substantial reduction in liquidity alongside sharply higher expenses reduces financial headroom during a period of launch and pipeline investment. This can constrain flexibility if commercialization takes longer than expected or development spending remains elevated over the coming quarters.
VEPPANU Financial Obligations
VEPPANU may expand the portfolio, but its contingent payments, royalties, and required development contribution could materially absorb future product economics. These commitments may pressure margins and cash generation, particularly before the product establishes a durable revenue base.
Rigel News
RIGL FAQ
What is Rigel’s market cap?
When is Rigel’s upcoming earnings report date?
How were Rigel’s earnings last quarter?
Is Rigel overvalued?
Does Rigel pay dividends?
What is Rigel’s EPS estimate?
What happened to Rigel’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rigel?
What is the TipRanks Smart Score and how is it calculated?
Rigel Stock Smart Score
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Raul R. Rodriguez
- Employees
- 173
- Website
- www.rigel.com
- Address
- 611 Gateway Boulevard, South San Francisco, CA, 94080, US
Rigel (RIGL) Earnings & Revenues
RIGL Company Deck
RIGL Earnings Call
Earnings Call SentimentPositive
The call presented multiple meaningful commercial and pipeline achievements—most notably the in‑license and imminent launch of VEPPANU with strong phase III efficacy, ongoing commercial revenue growth (14% product sales growth, record TAVALISSE quarter, 27% REZLIDHIA growth), and promising early R289 data with regulatory incentives. These positives are tempered by lower year‑over‑year net income (partly due to one‑time prior‑year items), a substantial decline in cash reserves (~38.5%), higher operating expenses (+~35.7%), modest decline in GAVRETO sales, and significant upfront/milestone/royalty obligations tied to VEPPANU that may pressure margins and cash flow. Overall, the company communicated confident launch readiness and an optimistic strategic trajectory but with near‑term financial and execution risks to monitor.
View all CH:RIGL earnings summaries